Champions Oncology, Inc. — Form 10-Q Summary
Business context and period. Champions Oncology develops TumorGraft-based oncology services for physicians and patients through Personalized Oncology Solutions (POS), and for pharmaceutical and biotechnology companies through Translational Oncology Solutions (TOS). This unaudited report covers the three months ended July 31, 2012, the first quarter of fiscal 2013, with comparison to the three months ended July 31, 2011. Dollar amounts below are in millions unless stated otherwise.
Financial performance and position
| Metric | Q1 FY2013 | Q1 FY2012 |
|---|---|---|
| Revenue | $2.106 | $1.634 |
| POS revenue | $0.918 | $0.601 |
| TOS revenue | $1.188 | $1.033 |
| Operating loss | $(1.599) | $(2.214) |
| Net loss | $(1.323) | $(2.037) |
| Basic and diluted loss per share | $(0.03) | $(0.04) |
| Cash used in operating activities | $(1.806) | $(1.535) |
- Revenue grew 31% year over year. POS increased 50%, attributed to 13 drug studies completed versus one in the prior-year quarter; TOS increased 20%, primarily from more models sold.
- Disclosed gross margins declined: POS to 11% from 17%, and TOS to 42% from 60%. Management attributed the reductions to costs of moving laboratory work in-house and investing in lab infrastructure and staffing.
- Total costs and operating expenses were $3.705 million, down 4% year over year. General and administrative expense fell 35% to $1.138 million, primarily from lower stock-based compensation and consulting costs; R&D declined 20% to $0.387 million.
- Cash and cash equivalents were $2.916 million at July 31, down from $4.716 million at April 30, 2012. Working capital was $1.2 million. Total assets were $5.145 million; total liabilities were $2.823 million. The balance sheet reports no borrowing debt; the company also states it has no off-balance-sheet debt or similar obligations. Stockholders’ deficit was $5.837 million.
- Operating cash use increased by $0.271 million year over year, which management attributed to higher working-capital requirements. Investing cash use was $0.019 million; there was no financing cash flow in the quarter.
- Stock-based compensation was $0.739 million. A noncash $0.285 million gain from the change in fair value of warrant liability reduced the reported net loss; the liability fell from $0.555 million to $0.270 million.
Changes, outlook, and risks
- Management said the POS strategy continues to emphasize core TumorGraft implants and drug studies, with reduced pricing intended to broaden access. Sales and marketing efforts were increased, and management expects future POS revenue to be driven by core products.
- The transition of laboratory work from a third-party CRO to the company’s Baltimore facility was substantially complete in the quarter. Management expects in-house operations to reduce future service costs as capacity utilization increases, while noting investment is being made to support expected volume.
- Management believed cash on hand would fund operations at least through April 30, 2013, and was exploring financing options. It cautioned that additional capital might not be available on acceptable terms; debt could carry high interest or restrictive covenants, while equity financing could dilute existing holders or have preferential rights.
- Investors in the 2011 private placement hold a contingent cash put right at $0.75 per share upon a change of control or sale of substantially all assets, subject to termination conditions. The related 12.533 million shares are classified as redeemable common stock. Warrants also have exercise-price reset provisions.
- Registration-rights penalties could reach $41,000 per 30-day period if a registration default occurs; the company considered payment not probable and recorded no accrual. Cephalon agreement milestone payments of up to $27 million are contingent on compound performance, clinical testing, and FDA approval; none had been achieved. A separate drug license provides for up to $3 million in development milestones if achieved.
- The company reported no litigation as of the filing date and no material changes to previously disclosed risk factors. Management concluded disclosure controls were effective and reported no material change in internal control over financial reporting.
Most important facts to verify
- Whether revenue growth and completed POS studies continue, and whether POS and TOS margins recover as the in-house lab is utilized.
- Cash burn, working-capital needs, and the timing and terms of any additional financing, given the stated cash runway through April 30, 2013.
- Potential dilution and contingent obligations from the redeemable shares, warrant reset and put provisions, and outstanding options and warrants.
- Progress and conditions for Cephalon milestones and royalties, and whether any registration-rights penalties or licensing obligations become payable.